
A single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.

A single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.

Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.

Experts from AASLD’s The Liver Meeting 2026 share the research they expect to most shape liver care, from new biomarkers to emerging MASH drugs.

Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections could shape legislation.

Mike Sharma, MD, discusses the asundexian trial’s broad patient population, results across stroke subtypes, and bleeding outcomes.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.

The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to optimize care.

Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles antibody.

Establishing baseline oxygen and cognitive assessments helps community teams safely treat older, higher-risk patients, says Salman Fazal, MD.

Diabetes and functional dependence predicted 3-year graft loss after MASH liver transplant, while machine learning showed limited predictive power.

In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.

Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, MD.

Àlvar Agustí, MD PhD; Jadwiga A. Wedzicha, MD; and 3 other experts say earlier diagnosis and intervention could most improve COPD outcomes within 5 years.

SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some patients.

Harvard Medical School’s Emily S. Wan, MD, discusses mucus plugs in COPD, how to detect them, and what would make them a treatment target.

The University of Exeter’s David Halpin, MA, DPhil, discusses inhaler device selection, single vs multiple inhalers, and the pharmacist’s role in COPD.

Baylor College of Medicine’s Francesca Polverino, MD, PhD, discusses interleukin-33 and mucus plugging.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

Imperial College London’s Jadwiga A. Wedzicha, MD, discusses anti-alarmin trial results in COPD and where biologics may fit in treatment.

Àlvar Agustí, MD, PhD, discusses what is new in the 2027 GOLD report and why the traditional narrative of COPD needs to change.

Gerald Criner, MD, outlines which patients with advanced COPD may need oxygen, home NIV, or high-flow therapy and when to discuss goals of care.

In an interview at AMCP Nexus 2026, Carmen Witsken, PharmD, of ACHP, outlined a proposed national risk pool for the costliest cell and gene therapies.

In part 2, Susan M. Wescott, RPh, MBA, discusses how payers navigate evidence gaps, prior authorization, and access to rare disease therapies.